Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence of Cardiovascular Diseases
3.4.2. Technological Advancements in Stent Design
3.4.3. Growing Geriatric Population
3.5. Market Restraint Analysis
3.5.1. High Cost of Drug Eluting Stents
3.6. Penetration And Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Drug Eluting Stent Market: Coating Type Segment Analysis
4.1. Drug Eluting Stent: Market Share Analysis, 2022 & 2030
4.2. Polymer-Based Coating
4.2.1. Polymer-Based Coating Market, 2018 – 2030 (USD Billion)
4.2.1.1. Non-Biodegradable Polymers
4.2.1.2. Biodegradable Polymers
4.3. Polymer-free Coating
4.3.1. Polymer-Free Coating Market, 2018 – 2030 (USD Billion)
4.3.1.1. Micro Porous Surface
4.3.1.2. Micro Structured Surface
4.3.1.3. Slotted Tubular Surface
4.3.1.4. Nanoporous Surface
Chapter 5. Drug Eluting Stent Market: Application Segment Analysis
5.1. Drug Eluting Stent: Market Share Analysis, 2022 & 2030
5.2. Coronary Artery Disease
5.2.1. Coronary Artery Disease Market, 2018 – 2030 (USD Billion)
5.3. Peripheral Artery Disease
5.3.1. Peripheral Artery Disease Market, 2018 – 2030 (USD Billion)
Chapter 6. Drug Eluting Stent Market: Regional Analysis
6.1. Drug Eluting Stent Market Share, By Region, 2022 & 2030
6.2. North America
6.2.1. North Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. U.S. Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Canada Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3. Europe
6.3.1. Europe Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. UK Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Germany Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. France Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Italy Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Spain Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Denmark Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Sweden Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Norway Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4. Asia Pacific
6.4.1. Asia Pacific Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Japan Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. China Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. India Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Australia Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Thailand Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. South Korea Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.5. Latin America
6.5.1. Latin America Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Brazil Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Mexico Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Argentina Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.6. MEA
6.6.1. MEA Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. South Africa Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Saudi Arabia Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. UAE Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Kuwait Drug Eluting Stent Market, 2018 – 2030 (USD Billion)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Share Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. Abbott Laboratories
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Boston Scientific Corporation
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Terumo Corporation
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Medtronic
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Biosensors International
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Cook Medical
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. B. Braun
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Biotronik
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Lepu Medical Technology
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 List of Secondary Sources |
